Home » Stocks » PDSB

PDS Biotechnology Corporation (PDSB)

Stock Price: $4.40 USD -0.26 (-5.58%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $4.62 +0.22 (5.00%) May 12, 6:18 PM
Market Cap 103.82M
Revenue (ttm) n/a
Net Income (ttm) -14.85M
Shares Out 16.75M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $4.40
Previous Close $4.66
Change ($) -0.26
Change (%) -5.58%
Day's Open 4.48
Day's Range 4.26 - 4.66
Day's Volume 348,210
52-Week Range 0.82 - 7.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PDS Biotechnology Corporation (NASDAQ: PDSB) will be reporting preliminary Phase 2 clinical data of its lead compound PDS0101 for the treatment of advanced HPV-associated cancers in patients whose cance...

1 week ago - Benzinga

FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacci...

1 week ago - GlobeNewsWire

FLORHAM PARK, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacci...

2 weeks ago - GlobeNewsWire

Florham Park, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccine...

3 weeks ago - GlobeNewsWire

FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacci...

1 month ago - GlobeNewsWire

PDS Biotech (PDSB) stock is heading higher on Thursday after announcing funding for the company's vaccine for the novel coronavirus. The post PDSB Stock: Why PDS Biotech Is Blasting Higher Today appeare...

2 months ago - InvestorPlace

Development and commercialization of novel T-cell activating vaccine to be performed in Brazil by consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica Development and commercializ...

2 months ago - GlobeNewsWire

FLORHAM PARK, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacci...

2 months ago - GlobeNewsWire

FLORHAM PARK, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacci...

2 months ago - GlobeNewsWire

Brazilian-based Blanver brings depth of expertise in development and commercialization of innovative pharmaceuticals across Latin America Brazilian-based Blanver brings depth of expertise in development...

2 months ago - GlobeNewsWire

Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment

3 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...

4 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...

4 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...

5 months ago - GlobeNewsWire

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities ...

5 months ago - Insider Monkey

Granted methods patent for Versamune® platform by the United States Patent and Trademark Office Granted methods patent for Versamune® platform by the United States Patent and Trademark Office

5 months ago - GlobeNewsWire

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency PDS0203 prioritized for clinical development by PDS Biotech and F...

6 months ago - GlobeNewsWire

VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients VERSATILE-002 Trial for First Line Treatm...

6 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...

6 months ago - GlobeNewsWire

PDS Biotech progresses second Phase 2 human clinical trial of PDS0101 PDS Biotech progresses second Phase 2 human clinical trial of PDS0101

6 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...

7 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer the...

7 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer the...

8 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc...

8 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing novel cance...

8 months ago - GlobeNewsWire

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc...

8 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer ther...

9 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer ther...

9 months ago - GlobeNewsWire

FLORHAM PARK, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc...

9 months ago - GlobeNewsWire

Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccination Versamune-CoV-2 (PDS0203) g...

9 months ago - GlobeNewsWire

PDS Biotech ramps up third infectious disease vaccine program, PDS0202 for influenza, following PDS0201 for tuberculosis and PDS0203 for COVID-19 PDS Biotech ramps up third infectious disease vaccine pr...

9 months ago - GlobeNewsWire

As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you today.

Other stocks mentioned: BCRX, ECOR, TTPH, CRDF
10 months ago - Forbes

NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020 NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020

10 months ago - GlobeNewsWire

Brazilian government to provide initial funding support to progress development of Versamune®-based vaccine to prevent COVID-19 infection

10 months ago - GlobeNewsWire

FLORHAM PARK, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc...

10 months ago - GlobeNewsWire

Wall Street sell-side analysts have issued buying recommendation ratings for shares of PDS Biotechnology Corp (NASDAQ:PDSB) and Hoth Therapeutics Inc (NASDAQ:HOTH), even though these stocks have fallen ...

Other stocks mentioned: HOTH
10 months ago - GuruFocus

FLORHAM PARK, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc...

11 months ago - GlobeNewsWire

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

FLORHAM PARK, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacci...

11 months ago - GlobeNewsWire

NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation ...

1 year ago - GlobeNewsWire

Expanded infectious disease program to address current and potential pandemics builds on existing tuberculosis collaboration

1 year ago - GlobeNewsWire

PRINCETON, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on ...

1 year ago - GlobeNewsWire

PDS Biotechnology (PDSB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

PRINCETON, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s propriet...

1 year ago - GlobeNewsWire

PRINCETON, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprieta...

1 year ago - GlobeNewsWire

PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprieta...

1 year ago - GlobeNewsWire

PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprieta...

1 year ago - GlobeNewsWire

About PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treat... [Read more...]

Industry
Biotechnology
CEO
Frank Bedu-Addo
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
PDSB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is 8.35, which is an increase of 89.77% from the latest price.

Price Target
$8.35
(89.77% upside)
Analyst Consensus: Strong Buy